Clinical trial
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable…
NCT00112463 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00112463 |
|---|---|
| Title | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
| Official title | A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma and 10 more |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 40 |
| Start date | Jan 7, 2005 |
| Primary completion | Oct 23, 2008 |
| Completion | Oct 23, 2008 |
| First posted | Jun 3, 2005 |
| Last update posted | Jun 14, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: